Does Viibryd Suppress Dopamine and Nitric Oxide?
No, Viibryd (vilazodone) does not suppress dopamine or nitric oxide—in fact, it has minimal binding affinity for dopamine reuptake sites and no documented mechanism for suppressing nitric oxide production.
Dopamine Activity
According to the FDA label, vilazodone demonstrates very weak binding to dopamine reuptake sites (Ki=37 nM), which is approximately 370-fold lower affinity compared to its serotonin reuptake binding (Ki=0.1 nM) 111. This means vilazodone essentially does not interact meaningfully with dopamine transporters at therapeutic doses.
Key Pharmacodynamic Evidence:
- Vilazodone selectively inhibits serotonin reuptake (IC50=1.6 nM) but shows negligible activity at dopamine reuptake sites 1
- The drug's mechanism centers on serotonin enhancement through selective serotonin reuptake inhibition combined with 5-HT1A partial agonist activity 11
Research Findings on Dopamine Systems:
Preclinical studies actually show vilazodone modulates rather than suppresses dopaminergic activity:
- In rat models, vilazodone decreased firing rates of ventral tegmental area (VTA) dopamine neurons after 2-14 days of administration 2
- However, in Parkinson's disease models, vilazodone reduced L-DOPA-induced dyskinesia without interfering with L-DOPA's prokinetic (dopamine-enhancing) effects, suggesting it does not suppress therapeutic dopamine activity 345
Clinical implication: The drug's effects on dopamine neurons appear to be indirect regulatory effects through serotonergic modulation, not direct dopamine suppression.
Nitric Oxide Activity
There is no evidence in the FDA label or available research that vilazodone affects nitric oxide production or signaling 111.
The only reference to nitric oxide in the provided evidence relates to melatonin's effects on viral infections—completely unrelated to vilazodone's mechanism 6. This appears to be an irrelevant cross-contamination in the evidence base.
What Vilazodone Actually Does:
The drug's established mechanism involves:
- Selective serotonin reuptake inhibition (primary mechanism)
- 5-HT1A receptor partial agonism (secondary mechanism)
- No clinically relevant activity at norepinephrine (Ki=56 nM) or dopamine transporters 1
Clinical Bottom Line
Vilazodone does not suppress dopamine or nitric oxide systems. Its pharmacological profile is highly selective for serotonergic mechanisms. Any concerns about dopamine suppression are unfounded based on both FDA-approved labeling and research evidence. The drug's weak dopamine binding affinity is pharmacologically insignificant at therapeutic doses.